Disseminated Primary Cutaneous Marginal Zone Lymphoma When First-Line Therapy Fails to Achieve Complete Response

Clinical Scenario

This protocol addresses patients with disseminated primary cutaneous marginal zone lymphoma in whom prior systemic or local therapy did not result in a complete response of the cutaneous lymphoma.

First-Line Treatment & Failure Condition

Initial management of disseminated disease typically involves intravenous rituximab, subcutaneous interferon-alpha, or low-dose local radiation therapy for palliation. When none of these approaches achieves a complete response of the cutaneous lymphoma, escalation to the next treatment line is indicated.

Next-Line Approach

For patients whose disease did not fully respond to first-line therapy, current evidence supports a rituximab-based combination regimen — the full treatment algorithm and clinical decision pathway are detailed in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers12061497

Disseminated lesions may be treated with intravenous rituximab, an anti-CD20 monoclonal antibody.

Recently rituximab has also been combined with lenalidomide.

A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphomas showed encouraging results with a significantly increased PFS (hazard ratio of 0.46, 95% CI, 0.34 to 0.62).

View source ↗